Stevens-Johnson syndrome (SJS) is an acute inflammatory vesiculobullous reaction of the skin and mucous membranes such as the ocular surface, oral cavity, and genitals. It is rare but often associated with inciting drugs and/or infectious agents[@b1][@b2][@b3]. In patients with extensive skin detachment and a poor prognosis the condition is called toxic epidermal necrolysis (TEN)[@b4]. The annual incidence of SJS and TEN has been reported as 1--6 and 0.4--1.0 cases per million persons, respectively[@b3][@b5] and the mortality rate as 3% and 27%, respectively[@b6].

The association between human leukocyte antigen (HLA) genotypes and drug-induced severe cutaneous adverse reactions (SCAR) including SJS/TEN has been reported. In Taiwanese Han Chinese patients the *HLA-B\*15:02* allele exhibited a very strong association with carbamazepine-induced SJS/TEN[@b7]. Similarly, in Japanese-[@b8] and European individuals[@b9] the *HLA-A\*31:01* allele was strongly associated with carbamazepine-induced SCAR including SJS/TEN and drug-induced hypersensitivity syndrome (DIHS). Allopurinol, a uric acid-lowering drug, often induced SCAR including SJS, TEN and DIHS, and allopurinol-induced SCARs were strongly associated with *HLA-B\* 58:01* in Han Chinese-[@b10], Caucasian-[@b11], and Japanese patients[@b12], suggesting that different ethnic groups may share the same risk factor for allopurinol-induced SCARs. Mockenhaupt et al.[@b13] reported that allopurinol and anticonvulsants such as carbamazepine are the main inciting drugs for SJS/TEN; we[@b14] and others[@b2][@b4] found that cold medicines including non-steroidal anti-inflammatory drugs (NSAIDs) and multi-ingredient cold medications are also major causative drugs for SJS/TEN. However, there have been no reports on the association between HLA genotypes and cold medicines in patients with SCAR.

Many SJS/TEN survivors suffer severe sequelae such as visual disturbance due to severe ocular surface complications (SOC) in the acute phase of the disease. In our earlier study of 71 Japanese SJS/TEN patients we reported the strong association between *HLA-A\*02:06* and SJS/TEN with SOC[@b15]. We found that a considerable number of these patients used cold medicines to treat the common cold[@b14]. Therefore, in this study we focused on a possible association between HLA genotypes and cold medicine (NSAIDs and analgesics)-related SJS/TEN (CM-SJS/TEN) with severe mucosal involvement including SOC.

Results
=======

HLA-type associated with CM-SJS/TEN with SOC
--------------------------------------------

First we compared the carrier frequencies of HLA alleles in the 131 CM-SJS/TEN with SOC patients and in 419 controls. The results are summarized in [](#t1){ref-type="table"}[Table 2](#t2){ref-type="table"}.

*HLA-A: HLA-A\*02:06* was strongly associated with CM-SJS/TEN with SOC (p = 2.8 × 10^−16^, Pc = 4.8 × 10^−15^, odds ratio (OR) = 5.7). *HLA-A\*24:02* was inversely associated with CM-SJS/TEN with SOC (p = 3.9 × 10^−4^, Pc = 0.0066, OR = 0.5). *HLA-A\*03:01* was weakly associated with the risk for- and *HLA-A\*11:01* was weakly associated with resistance to CM-SJS/TEN with SOC; the association was not significant after Bonferroni correction.

*HLA-B: HLA-B\*13:01, HLA-B\*44:02, HLA-B\*44:03*, and *HLA-B\*46:01* were weakly associated with CM-SJS/TEN with SOC; the association was not significant after correction. *HLA-B\*15:01, HLA-B\*52:01* and *HLA-B\*54:01* were weakly inversely associated with CM-SJS/TEN with SOC; the association was not significant after correction.

*HLA-C: HLA-C\*03:04* and *HLA-C\*05:01* were weakly associated- and *HLA-C\*12:02* was weakly and inversely associated with CM-SJS/TEN with SOC; the association was not significant after correction.

Next, to confirm these associations we compared the carrier frequency of HLA alleles with p values less than 0.05 before Bonferroni correction in the 131 CM-SJS/TEN with SOC of Group 1a, in another 20 CM-SJS/TEN with SOC patients (Group 2a) and 220 healthy controls of Group2.

In Group 2a (n = 20), *HLA-A\*02:06* and *HLA-B\*44:03* were significantly associated with CM-SJS/TEN with SOC (p = 0.0014, Pc = 0.0056, OR = 5.2 and p = 0.0058, Pc = 0.0406, OR = 4.22, respectively) ([Table 3](#t3){ref-type="table"}). However, the other HLA alleles examined were not significantly associated. Although the patient backgrounds were a little bit different in Groups 1a and 2a (1a: CM-SJS/TEN with SOC as sequelae, 2a: CM-SJS/TEN with SOC in the acute phase), we identified the same HLA types, *HLA-A\*02:06* and *HLA-B\*44:03*, as risk factors for CM-SJS/TEN with SOC.

As we observed the same tendency in Groups 1a and 2a, we combined the 151 CM-SJS/TEN with SOC patients (Group 1a, n = 131; Group 2a, n = 20) to compare the carrier frequencies of *HLA-A\*02:06* and *HLA-B\*44:03* with the frequencies in the 639 combined healthy controls. (Group 1, n = 419; Group 2, n = 220). The combined data revealed a strong association of *HLA-A\*02:06* and *HLA-B\*44:03* with CM-SJS/TEN with SOC (*HLA-A\*02:06*, p = 2.7 × 10^−20^, OR = 5.6; *HLA-B\*44:03*, p = 1.25 × 10^−3^, OR = 1.99) ([Table 4a](#t4){ref-type="table"}).

Comparison between CM-SJS/TEN with and without SOC
--------------------------------------------------

Among 16 CM-SJS/TEN without SOC patients (Group 2c), 2 carried *HLA-A\*02:06* and none carried *HLA-B\*44:03* ([Table 4b](#t4){ref-type="table"}). These carrier frequencies did not differ significantly from the Group 2 controls (p = 1.000 and p = 0.2324, respectively). These results suggest that *HLA-A\*02:06* and *HLA-B\*44:03* are not common risk factors for both CM-SJS/TEN with and without SOC, but were risk factors for only CM-SJS/TEN with SOC.

For further confirmation we compared the carrier frequency of both HLA alleles in the 151 combined CM-SJS/TEN with SOC patients (Group 1a, n = 131, Group 2a, n = 20) and in the 16 CM-SJS/TEN without SOC patients in Group 2c. The carrier frequencies of both alleles were significantly higher in the CM-SJS/TEN with SOC (Group 1a + Group 2a) than in the CM-SJS/TEN without SOC (Group 2c) (*HLA-A\*02:06*, p = 0.00812, OR = 6.2; *HLA-B\*44:03*, p = 0.02023, OR = 11.59) ([Table 4b](#t4){ref-type="table"}).

Analysis of CM unrelated-SJS/TEN with SOC
-----------------------------------------

As shown in [Table 1](#t1){ref-type="table"}, Group 1d contained 14- and Group 2d contained 38 patients with CM unrelated (other medicine related) -SJS/TEN with SOC. Among the 14 CM unrelated-SJS/TEN with SOC patients from Group 1d, 3 carried *HLA-A\*02:06* and 4 carried *HLA-B\*44:03*. Among the 38 CM unrelated SJS/TEN with SOC patients from Group 2d, 4 manifested *HLA-A\*02:06* and 2 had *HLA-B\*44:03*. To obtain higher power, we combined the data from the 52 CM unrelated -SJS/TEN with SOC patients from Groups 1d (n = 14) and 2d (n = 38) and compared their carrier frequency with that of combined healthy volunteers (n = 639). As shown in [Table 4c](#t4){ref-type="table"}, the carrier frequencies of *HLA-A\*02:06* and *HLA-B\*44:03* were comparable in the 2 groups (52 CM unrelated -SJS/TEN with SOC patients and 639 controls) and the difference was not statistically significant.

Analysis of acetaminophen-SJS/TEN with SOC (AR-SJS/TEN with SOC)
----------------------------------------------------------------

Acetaminophen is contained as an analgesic in most cold medicines. At least 59 patients in Group 1b and 14 in Group 2b were known to have taken acetaminophen for a few \~ several days before the onset of SJS/TEN. Therefore we examined the association of *HLA-A\*02:06* and *HLA-B\*44:03* with acetaminophen-related SJS/TEN (AR-SJS/TEN) with SOC using the combined data (73 AR-SJS/TEN with SOC from 59 in Group 1b and 14 in Group 2b). In all 73 patients with AR-SJS/TEN with SOC, we found a significant association with both alleles (*HLA-A\*02:06*, p = 2.5 × 10^−15^, OR = 6.5; *HLA-B\*44:03*, p = 0.0059, OR = 2.2) ([Table 4d](#t4){ref-type="table"}).

Discussion
==========

In this study we examined possible HLA risk factors for CM-SJS/TEN with SOC using two independently collected data sets of Japanese SJS/TEN patients.

The carrier frequency of *HLA-A\*02:06*, which we reported to have a very strong association with causative drug-unspecified SJS/TEN with SOC[@b15][@b19], was significantly higher in CM-SJS/TEN with SOC patients than in the healthy controls. This significant association was maintained in AR-SJS/TEN with SOC.

On the other hand, the carrier frequency of *HLA-A\*02:06* in the 16 CM-SJS/TEN without SOC patients of Group 2c and the 52 CM-unrelated SJS/TEN with SOC patients from Groups 1d and 2d did not significantly differ from that in our healthy controls. These results suggest that *HLA-A\*02:06* is a risk factor for CM-SJS/TEN with SOC but not for CM-SJS/TEN without SOC or CM-unrelated SJS/TEN with SOC.

Moreover, *HLA-A\*02:06* and *HLA-B\*44:03* might not be primarily associated with only infection related SJS/TEN, because drug-unrelated SJS/TEN with SOC in KPUM, which seemed to be only infectious agents-related SJS/TEN, was not associated with *HLA-A\*02:06* and *HLA-B\*44:03* in our preliminary study ([Supplemental Table 1](#s1){ref-type="supplementary-material"}).

The carrier frequeny of *HLA-A\*02:06* in all of our healthy controls was 13.6% ([Tables 2](#t2){ref-type="table"} and [3](#t3){ref-type="table"}), indicating that *HLA-A\*02:06* is a very common allele in the Japanese. However, as it is very rare in Caucasians and less frequent in Southern Han Chinese[@b20], in these populations, this allele might not be a major risk factor for CM-SJS/TEN with SOC. We also found a significant association between *HLA-B\*44:03* and CM-SJS/TEN with SOC (including AR-SJS/TEN with SOC). This association was not detected in CM-SJS/TEN without SOC patients nor in CM-unrelated SJS/TEN with SOC patients. This again suggests *HLA-B\*44:03* as a risk factor for CM-SJS/TEN with SOC. Data on our controls ([Tables 2](#t2){ref-type="table"} and [3](#t3){ref-type="table"}) indicate that *HLA-B\*44:03* is a common *HLA-B* type in the Japanese population. Unlike *HLA-A\*02:06*, *HLA-B\*44:03* is observed in Asians, Caucasians and Africans[@b21]. Reports from the USA[@b22] and France[@b23][@b24] showed that the *HLA-B12* (*HLA-Bw44*) antigen was significantly increased in Caucasian SJS patients. The *HLA-B12* antigen is mainly coded by *HLA-B\*44:02* or *HLA-B\*44:03* (<http://www.allelefrequencies.net/>).

Cold medicines were reported to be major causative drugs in SJS/TEN in Europe[@b4] and in its drug safety communications, the U.S. Food and Drug Administration (<http://www.fda.gov/Drugs/DrugSafety/ucm363041.htm>) alerted to the possibility of serious skin reactions to acetaminophen. The significant association of HLA-B12 with SJS/TEN in European patients may be attributable to their genetic backgrounds. To determine whether *HLA-B\*44:03* is a common risk factor for CM-SJS/TEN with SOC in various populations, independent association studies in divergent ethnic groups are needed.

Because *HLA-A\*02:06* is rarely a haplotype with *HLA-B\*44:03* (<http://www.allelefrequencies.net/>), these two HLA alleles might be independent genetic risk factors that render the host susceptible to severe mucosal disorders and to severe sequelae such as visual disturbance when SJS/TEN develops after the administration of cold medicines including NSAIDs. In our study, 96 of 151 patients (63.6%) with CM-SJS/TEN with SOC (group 1, n = 131; group 2, n = 20) harbored either *HLA-A\*02:06* or *HLA-B\*44:03*. On the other hand, only 177 of our 639 controls (27.7%) had one of these *HLA* alleles.

Forman et al.[@b25] and Leaute-Labreze[@b26] reported other infectious agents as triggers of SJS/TEN. Elsewhere[@b27] we showed that rs3775296T/T, a SNP of *Toll-like receptor 3 (TLR3)*, was a risk factor for SJS/TEN with SOC and that the interaction between rs3775296T/T and *HLA-A\*02:06* exerted more than additive effects. TLR3 is a pattern-recognizing receptor related to innate immunity after viral infections that often produce common cold symptoms. Moreover, cold medicines such as acetaminophen and NSAIDs, including ibuprofen and loxoprofen, commonly down-regulate the production of prostanoid including PGE~2~. We also reported earlier that in our study population, EP3, which is one of the PGE~2~ receptors, polymorphisms were strongly associated with SJS/TEN with SOC[@b14] and that the EP3 protein levels were much lower in the conjunctival epithelial cells of SJS/TEN patients than in the control subjects[@b14][@b28]. It is noteworthy that in our earlier study of SJS/TEN with SOC patients[@b14] about 80% had CM-SJS/TEN with SOC. It might be possible that not only cold medicine but cold medicine with infectious agent could cause CM-SJS/TEN with SOC, because the patients develop CM- SJS/TEN with SOC by taking cold medicines after having common cold induced by infectious agents. We believe that interactions between *HLA* risk factors detected in the current study and *TLR3*, and/or *EP3* might be keys in the pathogenesis of CM-SJS/TEN with SOC.

In summary, we reported the association between certain *HLA* types and CM-SJS/TEN with SOC. We propose that *HLA-A\*02:06* and *HLA-B\*44:03* be considered as strong risk factors for CM-SJS/TEN with SOC. Our findings may help to elucidate the pathogenesis of CM-SJS/TEN with SOC.

Methods
=======

Our study was approved by the institutional review board of Kyoto Prefectural University of Medicine, Kyoto, Japan, the National Institute of Health Sciences, Tokyo, Japan, and the Faculty of Medicine, University of Tokyo, Tokyo, Japan. All experimental procedures were conducted in accordance with the principles set forth in the Helsinki Declaration. The purpose of the study and the experimental protocols were explained to all participants and their prior written informed consent was obtained.

Patients and controls
---------------------

Japanese SJS/TEN patients (n = 236) were independently recruited at Kyoto Prefectural University of Medicine (KPUM)(Group 1, n = 162) and by the Japan Severe Adverse Reactions Research Group, mainly conducted by the National Institute of Health Sciences (NIHS) (Group 2, n = 74).

Between October 2004 and May 2013, 162 SJS/TEN with SOC were treated at Kyoto Prefectural University of Medicine; of these, 71 were included in our previous study[@b15]. The diagnosis of SJS/TEN with SOC was based on a confirmed history of acute-onset high fever, serious mucocutaneous illness with skin eruptions, and the involvement of at least 2 mucosal sites including the oral cavity and ocular surface. Some of the patients had developed SJS/TEN many years before recruitment for this study. Of the 162 patients in Group 1, 131 patients had taken cold medicines such as NSAIDs and multi-ingredient cold medications for a few \~ several days before disease onset for common-cold symptoms; they were classified as CM-SJS/TEN with SOC (Group 1a). Although the specific drugs were not identified by all 131 CM-SJS/TEN with SOC patients, 59 of 131 CM-SJS/TEN with SOC patients (45%) reported taking medicines containing acetaminophen (AR-SJS/TEN with SOC, Group 1b). Among the 162 of SJS/TEN with SOC patients (Group 1), 14 patients (Group 1d) were classified as CM unrelated-SJS/TEN with SOC, because they manifested anticonvulsants-related SJS/TEN with SOC (n = 10) or SJS/TEN with SOC after being treated with antimalarial-, anticancer-, or anti-depressive agents or steroids n = 4). We also excluded 17 patients; in 9 SJS/TEN with SOC the drugs were unknown and in 8 SJS/TEN with SOC were not related to drugs.

Group 2 (n = 74) consisted of patients with newly-developed SJS/TEN; they were recruited between June 2006 and May 2013 by participating institutes or via a nation-wide blood sampling network operated by the NIHS in cooperation with the Ministry of Health, Labour and Welfare, the Pharmaceutical and Medical Devices Agency, and the Federation of Pharmaceutical Manufacturers\' Association of Japan. The criteria proposed by Bastuji-Garin et al.[@b16] were used for a diagnosis of SJS/TEN in this group.

Ocular surface complications were judged to be severe ocular complications (SOC) when pseudo-membrane formation and/or conjunctival or corneal epithelial defects were observed in the acute phase. As shown in [Table 1](#t1){ref-type="table"}, Group 2 (n = 74) consisted of 20 patients with CM-SJS/TEN with SOC (Group 2a), all but 6 of these presented with AR-SJS/TEN with SOC (Group 2b). Group 2 also included 16 patients with CM-SJS/TEN without SOC (Group 2c), and 38 patients with CM-unrelated-SJS/TEN with SOC (Group 2d). The background of the 236 patients with SJS/TEN in group1 and group2 is summarized in [Table 1](#t1){ref-type="table"}.

Healthy Japanese volunteers (n = 639) served as the controls. They were independently recruited by the University of Tokyo (n = 419)[@b17] and by Kyoto Prefectural University of Medicine (n = 220)[@b18] and served for comparison studies of patient groups 1 and 2, respectively. In this study we enrolled only mainland Japanese.

HLA genotyping
--------------

We analyzed *HLA-A, -B, and -C* of all 162 group 1 patients, which consist of 131 CM-SJS/TEN with SOC (group 1a), 14 CM-unrelated (other medicine related) SJS/TEN with SOC (group 1d), and 17 SJS/TEN with SOC excluded because of being drug-unrelated and detail unknown. We performed polymerase chain reaction (PCR) assays followed by hybridization with sequence-specific oligonucleotide probes (PCR-SSO) using commercial bead-based typing kits (Wakunaga, Hiroshima, Japan). In group 2 (n = 74) we performed high-resolution HLA typing with a sequence-based method using SeCoreA, -B, and -C, locus sequencing kits (Invitrogen Corp., Brown Deer, WI, USA) and ABI 3730 and 3130 DNA sequencers (Applied Biosystems, Foster City, CA, USA). HLA genotypes were assigned using Assign SBT- or Assign ATF software (versions 3.2.7b and 1.0.2.41; respectively, Conexio Genomics, Western Australia, Australia). We also genotyped all volunteers for *HLA-A, -B, and -C* using PCR-SSO and commercial bead-based typing kits (Wakunaga or One Lambda, CA, USA).

Statistical analysis
--------------------

We compared the carrier frequency of individual HLA alleles between our patients and controls based on the dominant model using the χ^2^-test (Labo Server software;World Fusion, Tokyo, Japan) or Fisher\'s exact test (JMP version 7.0.1 software; SAS Institute Japan Ltd., Tokyo, Japan). Significance levels were corrected with the Bonferroni correction for multiple comparisons.
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###### Demographic and background data of patients and controls

  Explaination of subjects                                                                                                      Group 1 (KPUM)                                                              Group 2 (NIHS)  
  ------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------- ---------------- -------------
  a                                                                        Number of SJS/TEN patients with SOC who had taken cold medicines for treatment of common cold (CM-SJS/TEN with SOC group)             131             20
                                                                                                                                  Female/Male                                                                   80/51           14/6
                                                                                                                        Age of onset (years, mean ± SD)                                                      26.6 ± 17.5     54.0 ± 17.7
  b (which are included in a)                                         Number of SJS/TEN patients with SOC who had taken acetaminophen for treatment of common cold (Acetaminophen-SJS/TEN with SOC group)       \(59\)         \(14\)
                                                                                                                                  Female/Male                                                                   37/22            9/5
                                                                                                                        Age of onset (years, mean ± SD)                                                      31.1 ± 15.8     35.2 ± 16.9
  c                                                                       Patients with SJS/TEN without SOC who had taken cold medicines for treatment of common cold (CM-SJS/TEN without SOC group)                             16
                                                                                                                                  Female/Male                                                                     \-             9/7
                                                                                                                        Age of onset (years, mean ± SD)                                                                      62.0 ± 25.0
  d                                                                      Patients with SJS/TEN with SOC who had taken medicines not for treatment of common cold (CM unrelated-SJS/TEN with SOC group)            14             38
                                                                                                                                  Female/Male                                                                    11/3           19/19
                                                                                                                        Age of onset (years, mean ± SD)                                                      44.8 ± 19.3     57.4 ± 23.1
  the samples excluded because of drug unrelated or detail unknown                                                                    17                                                                          \-        
  total number of the SJS/TENpatients                                                                                                 162                                                                         74        
  Controls                                                                                                                    Healthy volunteers                                                                 419             220
                                                                                                                                  Female/Male                                                                   350/69         131/89
                                                                                                                            Age (years, mean ± SD)                                                                \-         35.5 ± 11.0

CM-SJS/TEN: Cold medicine-related SJS/TEN.

SOC: severe ocular surface complications.

KPUM: Kyoto Prefectural University of Medicine, NIHS: National Institute of Health Sciences.

###### Results of association analysis for HLA types and CM-SJS/TEN with SOC in Group 1 (KPUM)

  HLA genotype    Carrier frequency (%)   Dominant model analysis                                  
  -------------- ----------------------- ------------------------- --------------- --------------- -------------------------
  HLA-A                                                                                                         
  *A\*02:06*         62/131 (47.3%)           57/419 (13.60%)       **2.79.E-16**   **4.75E-15**    **5.71 (3.666-8.881)**
  *A\*03:01*          5/131 (3.82%)            4/419 (0.95%)         **0.0242**         0.412         4.12 (1.089-15.564)
  *A\*11:01*          10/131 (7.6%)           71/419 (16.95%)       **8.67.E-03**       0.147         0.405 (0.202-0.811)
  *A\*24:02*         57/131 (43.5%)          256/419 (61.10%)       **3.89.E-04**   **6.60.E-03**   **0.490 (0.330-0.730)**
  HLA-B                                                                                                         
  *B\*13:01*          10/131 (7.6%)           13/419 (3.10%)         **0.0237**         0.807         2.58 (1.104-6.032)
  *B\*15:01*          11/131 (8.4%)           69/419 (16.47%)        **0.0222**         0.755         0.465 (0.238-0.908)
  *B\*44:02*          5/131 (3.82%)            5/419 (1.19%)         **0.0498**         1.69          3.29 (0.936-11.532)
  *B\*44:03*         31/131 (23.7%)           66/419 (15.75%)        **0.0381**         1.29          1.66 (1.024-2.682)
  *B\*46:01*         22/131 (16.8%)           38/419 (9.07%)         **0.0133**         0.453         2.02 (1.148-3.566)
  *B\*52:01*          12/131 (9.2%)           79/419 (18.85%)       **9.16.E-03**       0.311         0.434 (0.228-0.825)
  *B\*54:01*          10/131 (7.6%)           61/419 (14.56%)        **0.0391**         1.33          0.485 (0.241-0.976)
  HLA-C                                                                                                         
  *C\*03:04*         42/131 (32.1%)           98/419 (23.39%)        **0.0467**         0.841          1.55 (1.00-2.38)
  *C\*05:01*          5/131 (3.82%)            5/419 (1.19%)         **0.0498**         0.897         3.29 (0.936-11.532)
  *C\*12:02*          13/131 (9.9%)           80/419 (19.09%)        **0.0145**         0.262         0.467 (0.251-0.870)

P: P values obtained with χ^2^-tests.

Pc: P values corrected for the multiplicity of testing by the number of comparisons (17, 34, and 18 for *HLA-A*, *HLA-B* and *HLA-C*, respectively).

CM-SJS/TEN: cold medicine related SJS/TEN who had taken cold medicine.

SOC: severe ocular surface complications.

CI: confidence interval.

###### Results of association analysis between HLA types and CM-SJS/TEN with SOC in Group 2 (NIHS)

                Carrier frequency (%)   Dominant model analysis                             
  ------------ ----------------------- ------------------------- ------------ ------------- ------------------------
  *HLA-A*                                                                                               
  *A\*02:06*        9/20 (45.0%)            30/220 (13.6%)        **0.0014**   **0.00560**   **5.18 (1.98--13.56)**
  *A\*03:01*          0/20 (0%)              19/220 (8.6%)          0.3804                              
  *A\*11:01*        2/20 (10.0%)            39/220 (17.7%)          0.5408                              
  *A\*24:02*        14/20 (70.0%)           132/220 (60.0%)         0.4770                              
  *HLA-B*                                                                                               
  *B\*13:01*         2/20 (10%)              6/220 (2.7%)           0.1364                              
  *B\*15:01*         2/20 (10%)             39/220 (17.7%)          0.5408                              
  *B\*44:02*          0/20 (0%)              4/220 (1.8%)           1.0000                              
  *B\*44:03*        8/20 (40.0%)            30/220 (13.6%)        **0.0058**   **0.0406**    **4.22 (1.59--11.19)**
  *B\*46:01*         2/20 (10%)              18/220 (8.2%)          0.6764                              
  *B\*52:01*         1/20 (5.0%)            48/220 (21.8%)          0.0857                              
  *B\*54:01*         5/20 (25%)             33/220 (15.0%)          0.3316                              
  *HLA-C*                                                                                               
  *C\*03:04*         6/20 (30%)             43/220 (19.5%)          0.2573                              
  *C\*05:01*          0/20 (0%)              4/220 (1.8%)           1.0000                              
  *C\*12:02*         1/20 (5.0%)            47/220 (21.4%)          0.1388                              

P: p-values obtained by Fisher\'s exact tests are shown.

Pc: p-values corrected for the mutiplicity of testing by the number of comparisons: (4, 7 and 3 for HLA-A, HLA-B and HLA-C, respectively).

CM-SJS/TEN: cold medicine related SJS/TEN who had taken cold medicine.

SOC: severe ocular surface complications.

CI: Confidence interval.

###### Results of association analyses using combined SJS/TEN patients\' data

  a\. Comparison between CM-SJS/TEN with SOC (Group 1a and Group 2a) and combined healthy volunteers\' data                                                
  ----------------------------------------------------------------------------------------------------------- ---------------- ---------------- ---------- -------------------
  *A*[\*](#t4-fn1){ref-type="fn"}*02:06*                                                                       71/151 (47.0%)   87/639 (13.6%)   2.72E-20   5.63 (3.81--8.33)
  *B*[\*](#t4-fn1){ref-type="fn"}*44:03*                                                                       39/151 (25.8%)   95/639 (14.9%)   0.00125    1.99 (1.30--3.05)

  b\. Comparison between CM-SJS/TEN with SOC (Group 1a and Group 2a) and without SOC (Group 2c)                                             
  ----------------------------------------------------------------------------------------------- ---------------- -------------- --------- -------------------------------------------------
  *A*[\*](#t4-fn1){ref-type="fn"}*02:06*                                                            71/151 (47%)    2/16 (12.5%)   0.00812                 6.21 (1.36--28.28)
  *B*[\*](#t4-fn1){ref-type="fn"}*44:03*                                                           39/151 (25.8%)    0/16 (0%)     0.02023   11.59[\*](#t4-fn1){ref-type="fn"} (0.68--197.7)

  c\. Comparison of CM unrelated SJS/TEN with SOC and combined healthy volunteers\' data                                   
  ---------------------------------------------------------------------------------------- -------------- ---------------- -------
  *A*[\*](#t4-fn1){ref-type="fn"}*02:06*                                                    7/52 (13.5%)   87/639 (13.6%)   0.975
  *B*[\*](#t4-fn1){ref-type="fn"}*44:03*                                                    6/52 (11.5%)   95/639 (14.9%)   0.514

  d\. Comparison between Acetaminophen-SJS/TEN with SOC (Group 1b and Group 2b) and combined healthy volunteers\' data                                               
  ---------------------------------------------------------------------------------------------------------------------- --------------- ---------------- ---------- --------------------
  *A*[\*](#t4-fn1){ref-type="fn"}*02:06*                                                                                  37/73 (50.7%)   87/639 (13.6%)   2.54E-15   6.52 (3.91--10.88)
  *B*[\*](#t4-fn1){ref-type="fn"}*44:03*                                                                                  20/73 (27.4%)   95/639 (14.9%)    0.0059    2.16 (1.27--3.78)
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\*Woolf\'s correction.

P: P values obtained by χ^2^-tests.

CM-SJS/TEN: cold medicine related SJS/TEN who had taken cold medicine.

SOC: severe ocular surface complications.

CI: Confidence interval.
